Echinocandins Versus Azoles for Candidemia Treatment (AntiCandiTreat)

Civil Hospices of Lyon

Status

Completed

Conditions

Candidemia

Treatments

Drug: Echinocandin treatment

Drug: Triazole treatment

Study type

Observational

Funder types

Other

Identifiers

NCT03799172

CRC_GHN_2019_001

Details and patient eligibility

About

Candidemia is the most frequent invasive fungal disease in intensive care units (ICUs). It remains a major health concern, considering its attributable mortality up to 40% in critically ill patients. Successful clinical outcome requires early diagnosis and effective antifungal therapy. Guidelines for the treatment of candidemia were published by the Infectious Diseases Society of America (IDSA) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). According to these guidelines, echinocandins are the preferred first-line therapy for candidemia in critically ill patients. Considering the bibliography supporting this statement, the place of triazoles still needs to be defined in candidemia therapeutic arsenal. In this context, we are setting up a retrospective cohort study using Hospital database to compare the efficacy of echinocandins and azoles for the treatment of candidemia in intensive care units.

Enrollment

79 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients who had a diagnosis of candidemia during ICU stay and were treated with echinocandins or azoles

Exclusion criteria

Patients with neutropenia
Patients without antifungal treatment
Patients who received antifungal therapy for more than two days before candidemia diagnosis
Patients receiving liposomal amphotericin b or multiple antifungal agents as first-line therapy
Patients who received less than 4 days of antifungal therapy after candidemia diagnosis